| Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA … P Moreau, M Attal, C Hulin, B Arnulf, K Belhadj, L Benboubker, MC Béné, ... The Lancet 394 (10192), 29-38, 2019 | 955 | 2019 |
| Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and … M Cavo, F Gay, M Beksac, L Pantani, MT Petrucci, MA Dimopoulos, ... The Lancet Haematology 7 (6), e456-e468, 2020 | 346 | 2020 |
| Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR A Spencer, S Lentzsch, K Weisel, H Avet-Loiseau, TM Mark, I Spicka, ... Haematologica 103 (12), 2079, 2018 | 303 | 2018 |
| COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus L Scarfò, T Chatzikonstantinou, GM Rigolin, G Quaresmini, M Motta, ... Leukemia 34 (9), 2354-2363, 2020 | 271 | 2020 |
| Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial MA Dimopoulos, F Gay, F Schjesvold, M Beksac, R Hajek, KC Weisel, ... The Lancet 393 (10168), 253-264, 2019 | 253 | 2019 |
| The prevalence and prognostic value of low muscle mass in cancer patients: a review of the literature HN Rier, A Jager, S Sleijfer, AB Maier, MD Levin The oncologist 21 (11), 1396-1409, 2016 | 224 | 2016 |
| Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy JAC van Bruggen, AWJ Martens, JA Fraietta, T Hofland, SH Tonino, ... Blood, The Journal of the American Society of Hematology 134 (1), 44-58, 2019 | 162 | 2019 |
| Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy HN Rier, A Jager, S Sleijfer, J van Rosmalen, MCJM Kock, MD Levin The Breast 31, 9-15, 2017 | 151 | 2017 |
| First-line venetoclax combinations in chronic lymphocytic leukemia B Eichhorst, CU Niemann, AP Kater, M Fürstenau, J Von Tresckow, ... New England Journal of Medicine 388 (19), 1739-1754, 2023 | 139 | 2023 |
| Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities AP Kater, C Owen, C Moreno, G Follows, T Munir, MD Levin, O Benjamini, ... NEJM evidence 1 (7), EVIDoa2200006, 2022 | 139 | 2022 |
| Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant … P Moreau, C Hulin, A Perrot, B Arnulf, K Belhadj, L Benboubker, MC Bene, ... The Lancet Oncology 22 (10), 1378-1390, 2021 | 139 | 2021 |
| Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms MD Levin, JG den Hollander, B van der Holt, BJ Rijnders, M Van Vliet, ... Journal of Antimicrobial Chemotherapy 60 (5), 1104-1107, 2007 | 132 | 2007 |
| Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study MHJ Van Oers, K Kuliczkowski, L Smolej, M Petrini, F Offner, S Grosicki, ... The lancet oncology 16 (13), 1370-1379, 2015 | 121 | 2015 |
| Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma S Zweegman, B van der Holt, UH Mellqvist, M Salomo, GMJ Bos, ... Blood, The Journal of the American Society of Hematology 127 (9), 1109-1116, 2016 | 111 | 2016 |
| Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment I de Weerdt, T Hofland, R de Boer, JA Dobber, J Dubois, ... Blood advances 3 (17), 2642-2652, 2019 | 109 | 2019 |
| COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study T Chatzikonstantinou, A Kapetanakis, L Scarfò, G Karakatsoulis, D Allsup, ... Leukemia 35 (12), 3444-3454, 2021 | 87 | 2021 |
| Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology … GJ Ossenkoppele, G Stussi, J Maertens, K van Montfort, BJ Biemond, ... Blood, The Journal of the American Society of Hematology 120 (24), 4706-4711, 2012 | 79 | 2012 |
| Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, open-label, phase III trial P Sonneveld, A Chanan-Khan, K Weisel, AK Nooka, T Masszi, M Beksac, ... Journal of Clinical Oncology 41 (8), 1600-1609, 2023 | 71 | 2023 |
| Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections JG den Hollander, C van Arkel, BJ Rijnders, PJ Lugtenburg, S de Marie, ... Journal of Antimicrobial Chemotherapy 57 (6), 1248-1250, 2006 | 69 | 2006 |
| Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma IS Nijhof, LE Franssen, MD Levin, GMJ Bos, A Broijl, SK Klein, HR Koene, ... Blood, The Journal of the American Society of Hematology 128 (19), 2297-2306, 2016 | 63 | 2016 |
